ArticlePituitary2025
Anemia in acromegaly: Prevalence, etiologies, and predictors from a large tertiary center cohort.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGrowth hormone (GH) and insulin-like growth factor-1 (IGF-1) influence erythropoiesis; however, data on the prevalence and determinants of anemia in acromegaly are limited. This study aimed to investigate the frequency, characteristics, and risk factors of anemia in patients with acromegaly.
methodsWe retrospectively reviewed medical records of 381 patients with acromegaly followed at a tertiary referral center. Clinical, hormonal, radiological, and hematological data were analyzed.
resultsAnemia was identified in 219 of 381 patients with acromegaly (57.5%). Most cases were normocytic (67%) and of mild severity (45%), while moderate and severe anemia accounted for 11.3% and 0.8%, respectively. Iron deficiency anemia was present in 41 of 219 anemic patients (18.7%) more frequently in women than men (27/120 [22.5%] vs. 14/98 [14.3%]), and thalassemia minor was detected in 4% of cases. No folate- or vitamin B12-deficiency anemia was observed. The majority of anemic cases (77.3%) remained unexplained. Sex-specific analyses showed that microcytic anemia was predominantly seen in women (49/73, 67.1%), whereas normocytic anemia displayed a nearly equal distribution between men (74/145, 51.0%) and women (71/145, 49.0%). Compared with non-anemic patients, those with anemia more frequently had macroadenomas with invasive features, residual tumor on postoperative imaging, and hypopituitarism, together with higher postoperative GH, IGF-1, and prolactin levels (all p < 0.05). They required more intensive treatment, including somatostatin receptor ligands (SRLs) (71.1% vs. 49.7%), dopamine agonists (18.8% vs. 10.4%), and radiotherapy (29.8% vs. 9.2%). Cancer prevalence was also higher in anemic patients (17% vs. 10.4%), although not statistically significant. Multivariate analysis identified macroadenoma, SRL therapy, and L-thyroxine use as independent predictors of anemia.
conclusionAnemia is a frequent and clinically relevant comorbidity in acromegaly, associated with tumor burden, hypopituitarism, treatment intensity. These findings highlight the need for systematic evaluation of anemia in acromegalic patients and underscore the importance of future prospective studies to clarify its complex pathophysiology.
Indexed as
Identifiers
41359132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.